Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fluticasone/formoterol - Eurofarma

Drug Profile

Fluticasone/formoterol - Eurofarma

Alternative Names: Fluticasone propionate/formoterol fumarate dihydrate; Formoterol fumarate dihydrate/fluticasone propionate; Formoterol/fluticasone; Lugano®

Latest Information Update: 05 May 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eurofarma
  • Class Antiallergics; Antiasthmatics; Ethanolamines; Glucocorticoids; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Asthma

Most Recent Events

  • 19 Apr 2023 Preclinical trials in Asthma in Brazil (Inhalation) before April 2023
  • 19 Apr 2023 Eurofarma plans a phase III FORASMA trial for Asthma (In children, In adults, In the elderly) in Brazil (Inhalation) in July 2024 (NCT05735431)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top